Retraction
Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
Paper Information
Record ID:
39038
Author(s):
Journal:
Publication Date:
September 10, 2021
Retraction Date:
September 02, 2022
(3.2 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt
- Public Health and Community Medicine, Menoufia University, Menoufia, Egypt
- Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
- Chest Department, Tanta University, Tanta, Egypt
- Department of Anesthesia, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt
- School of Biotechnology, Badr University in Cairo, Badr City, Cairo 11829, Egypt
Country:
🇪🇬 EgyptArticle Type:
Publisher:
American Society of Tropical Medicine and Hygiene
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (59)
59
Total Citations29
Post-Retraction(49.2%)
30
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
20
Within 1 year
2
After 2+ years
833
Days since retraction (latest)
<i>In silico</i> design and discovery of pan coronavirus small molecule anti-virals targeting 3CL <sup>PRO</sup> protease
Satish Kumar Manjhi, Aman Achuthan Kattuparambil, Bibhudutta Mishra et al. (6 authors)
Journal of Biomolecular Structure and Dynamics
Published: Dec 2024
833 days after retraction
Reporting of Participant Race and Ethnicity from COVID-19 Randomized Controlled Drug and Biologicals Trials: A Scoping Review
Shelly Melissa Pranić, M. Dulce Estêvão, Lenny Vasanthan et al. (10 authors)
Epidemiologic Reviews
Published: Nov 2024
817 days after retraction
Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis
Behnam Amani, Bahman Amani
Reviews in Medical Virology
Published: Jun 2024
7 citations
7 citations
644 days after retraction
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19
Wang-Da Liu, Po‐Hao Feng, Chien‐Yu Cheng et al. (20 authors)
Infectious Diseases and Therapy
Open Access
Published: May 2024
627 days after retraction
Clinical outcomes of remdesivir in patients with COVID-19 infection: An observational study from a tertiary care hospital in Pakistan
Sher Muhammad Sethi, Memoona Irshad, Roodaba Iqbal
Infectious Diseases Journal of Pakistan
Open Access
Published: Mar 2024
574 days after retraction
Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review
Shelly Melissa Pranić, M. Dulce Estêvão, Lenny Vasanthan et al. (10 authors)
Research Square (Research Square)
Open Access
Published: Mar 2024
559 days after retraction
In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants
Calvin R. Wei, Zarrin Basharat, Godwin C. Lang’at
Drugs and Drug Candidates
Open Access
Published: Jan 2024
1 citation
1 citation
490 days after retraction
The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study
Mehran Amirizadeh, Ali Kharazmkia, Kobra Sharifi abdoli et al. (5 authors)
Health Science Reports
Open Access
Published: Nov 2023
3 citations
3 citations
425 days after retraction
The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis
Chuizhe Chen, Junde Fang, Shu Chen et al. (7 authors)
BMC Infectious Diseases
Open Access
Published: Oct 2023
18 citations
18 citations
402 days after retraction
In Silico Drug Discovery: The Next Frontier in the Fight Against SARS-CoV-2
Calvin R. Wei, Godwin C. Lang’at
Unknown Journal
Open Access
Published: Aug 2023
2 citations
2 citations
343 days after retraction
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Alexandre Naime Barbosa, Alberto Chebabo, Carlos Ernesto Ferreira Starling et al. (18 authors)
Annals of Clinical Microbiology and Antimicrobials
Open Access
Published: Aug 2023
8 citations
8 citations
339 days after retraction
Elevation of D-dimer levels are associated with early need for mechanical ventilation support in patients with COVID-19
Asmaa Ali, Liang Wu, Ahmed Samir Abdelhafiz et al. (9 authors)
BMC Pulmonary Medicine
Open Access
Published: Aug 2023
6 citations
6 citations
335 days after retraction
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Podjanee Jittamala, William HK Schilling, James A Watson et al. (83 authors)
The Journal of Infectious Diseases
Open Access
Published: Jul 2023
15 citations
15 citations
320 days after retraction
Effect of remdesivir on mortality rate, need of intubation and mechanical ventilation in COVID-19 positive patients: a retrospective observational study
Anand Nikalje, Srabani Tripathy, Rahul S. Talekar et al. (4 authors)
International Journal of Research in Medical Sciences
Open Access
Published: May 2023
1 citation
1 citation
269 days after retraction
Remdesivir Treatment Lacks the Effect on Mortality Reduction in Hospitalized Adult COVID-19 Patients Who Required High-Flow Supplemental Oxygen or Invasive Mechanical Ventilation
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin
Medicina
Open Access
Published: May 2023
6 citations
6 citations
266 days after retraction
"PHILIPPINE PEDIATRIC COVID-19 LIVING CLINICAL PRACTICE GUIDELINES as of March 2022"
Leonila F. Dans, Anna Lisa Ong‐Lim, Rosemarie Arciaga et al. (6 authors)
Pediatric Infectious Disease Society of the Philippines Journal
Open Access
Published: Apr 2023
1 citation
1 citation
212 days after retraction
Role of Supplements in the Management of COVID-19 - A Comprehensive Review
Rajkapoor Balasubramanian, Naina Mohamed Pakkir Maideen, Sudha Muthusamy et al. (5 authors)
Infectious Disorders - Drug Targets
Published: Mar 2023
2 citations
2 citations
189 days after retraction
The Impact of LEP rs7799039 Polymorphism and Obesity on the Severity of Coronavirus Disease-19
Amal Ahmed Mohamed, Abdulmohsen H Alrohaimi, Asmaa Sayed Abdelgeliel et al. (23 authors)
Diabetes Metabolic Syndrome and Obesity
Open Access
Published: Feb 2023
3 citations
3 citations
152 days after retraction
Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
British Journal of Clinical Pharmacology
Open Access
Published: Jan 2023
1 citation
1 citation
151 days after retraction
Remdesivir for the treatment of COVID-19
Felicitas Grundeis, Kelly Ansems, Karolina Dahms et al. (11 authors)
Cochrane library
Published: Jan 2023
90 citations
90 citations
145 days after retraction
Retraction of Clinical Trials about the SARS-CoV-2 Infection: An Unaddressed Problem and Its Possible Impact on Coronavirus Disease (COVID)-19 Treatment
Felipe Eduardo Valencise, Camila Vantini Capasso Palamim, Fernando Augusto Lima Marson
International Journal of Environmental Research and Public Health
Open Access
Published: Jan 2023
8 citations
8 citations
139 days after retraction
Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials
Golnaz Shams, Asma Kazemi, Khatereh Jafaryan et al. (6 authors)
Clinics
Open Access
Published: Jan 2023
9 citations
9 citations
121 days after retraction
Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil
Jonas Michel Wolf, Bianca Gubert Borges, Pamela Pereira Fagundes et al. (11 authors)
Clinical & Biomedical Research
Open Access
Published: Jan 2023
121 days after retraction
Potential Indonesian Natural Compound as antiviral for COVID-19 targeting the RdRp: In silico Study
Zahra Silmi Muscifa, Tony Sumaryada, Laksmi Ambarsari et al. (4 authors)
Molekul
Open Access
Published: Nov 2022
78 days after retraction
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Fatma Haddad, Ghadeer Dokmak, Rafik Karaman
Life
Open Access
Published: Nov 2022
22 citations
22 citations
60 days after retraction
The efficacy and safety of remdesivir and its combination with other drug for the treatment of COVID-19: a systematic review and meta-analysis
Chuizhe Chen, Junde Fang, Shu Chen et al. (7 authors)
Research Square (Research Square)
Open Access
Published: Oct 2022
49 days after retraction
Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?
Aidan M. Kirkham, Adrian Bailey, Risa Shorr et al. (6 authors)
Cytotherapy
Open Access
Published: Oct 2022
16 citations
16 citations
41 days after retraction
Current Therapeutic Strategies and Possible Effective Drug Delivery Strategies against COVID-19
Debabrata Ghosh Dastidar, Dipanjan Ghosh, Swarnasree Ghosh et al. (4 authors)
Current Drug Delivery
Published: Oct 2022
2 citations
2 citations
33 days after retraction
Re: Remdesivir for the treatment of COVID-19 by Lee et al.
Alessia Beccacece, Tommaso Ascoli Bartoli, Emanuele Nicastri
Clinical Microbiology and Infection
Open Access
Published: Oct 2022
32 days after retraction
Human ACE-2, MCP1 and micro-RNA 146 as Novel Markers for COVID- 19 Affection and Severity
Sherief Abd‐Elsalam, Amal Ahmed Mohamed, A. Abdelghani et al. (13 authors)
Infectious Disorders - Drug Targets
Published: Aug 2022
3 days before retraction
Corticosteroids: A boon or bane for COVID-19 patients?
Subhadeep Sen, Bhagat Singh, Goutam Biswas
Steroids
Open Access
Published: Aug 2022
12 citations
12 citations
9 days before retraction
Latest in COVID-19 Vaccine 'Candidates' Race
Manar Atoum, Dalia Abu Zreig, Laith Majed Abu Zreig
Infectious Disorders - Drug Targets
Published: Aug 2022
14 days before retraction
Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study
Ariyon Schreiber, Justin Bauzon, Kavita Batra et al. (17 authors)
Clinical Drug Investigation
Open Access
Published: Aug 2022
11 citations
11 citations
16 days before retraction
MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?
Andrea Sikora, Sultan Almuntashiri, Duo Zhang et al. (4 authors)
Infectious Disorders - Drug Targets
Open Access
Published: Jun 2022
3 citations
3 citations
73 days before retraction
COVID-19 Associated Acute Pancreatitis: A Case Series from India
Jitendra Singh, Nilesh Kumar, Kailash Kumar et al. (4 authors)
Infectious Disorders - Drug Targets
Published: May 2022
4 citations
4 citations
94 days before retraction
Epidemiological Study of COVID-19 in Iran and the World: A Review Study
Nasges Ansari, Samira Shokri, Mohadeseh Pirhadi et al. (5 authors)
Infectious Disorders - Drug Targets
Published: May 2022
2 citations
2 citations
98 days before retraction
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
Todd C. Lee, Srinivas Murthy, Olivier Del Corpo et al. (8 authors)
Clinical Microbiology and Infection
Open Access
Published: May 2022
74 citations
74 citations
106 days before retraction
An Updated and Focused Review on Heterocyclic Inhibitors for SARSCoV and SARS-CoV-2 3CLpro
Ozair Alam, Ajay Manaithiya, Shruti Mittal et al. (8 authors)
Mini-Reviews in Medicinal Chemistry
Published: May 2022
2 citations
2 citations
113 days before retraction
Demographic, Clinical, and Investigational Characteristics of COVID-19- related Guillain-Barré Syndrome with Differences from Typical and Another Virus-related Guillain-Barré Syndrome
Jitendra Singh, Nilesh Kumar, Anju Dinkar
Infectious Disorders - Drug Targets
Published: Apr 2022
7 citations
7 citations
126 days before retraction
‘Convalescent Plasma’- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review
Sumel Ashique, Tahamina Khatun, Garima Sahu et al. (8 authors)
Infectious Disorders - Drug Targets
Published: Apr 2022
1 citation
1 citation
129 days before retraction
COVID-19 Vaccination, Peltzman Effect and Possible Increase in Highrisk Behaviors: A Growing Concern Related to Risk Compensation and Reduced Compliance to Public Health Protective Measures after Vaccines Rollout
Shahab Falahi, Jasem Mohamadi, Hojjat Sayyadi et al. (8 authors)
Infectious Disorders - Drug Targets
Published: Apr 2022
14 citations
14 citations
135 days before retraction
A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 Patients
Tibor Bakács, Volker Sandig, Shimon Slavin et al. (7 authors)
Infectious Disorders - Drug Targets
Published: Apr 2022
2 citations
2 citations
135 days before retraction
COVID-19 and Coinfections: A Serious Health Threat Requires Combination of Diagnosis and Therapy
Shahid Nawaz, Maira Saleem
Infectious Disorders - Drug Targets
Published: Apr 2022
1 citation
1 citation
148 days before retraction
Therapeutic Strategies for COVID-19 Patients: An Update
Muhammad Ibrahim Getso, Soudabeh Etemadi, Vahid Raissi et al. (7 authors)
Infectious Disorders - Drug Targets
Published: Mar 2022
163 days before retraction
An Updated Review on Complicated Mechanisms of COVID-19 Pathogenesis and Therapy: Direct Viral Damage, Renin-angiotensin System Dysregulation, Immune System Derangements, and Endothelial Dysfunction
Shahab Falahi, Maryam Maleki, Azra Kenarkoohi
Infectious Disorders - Drug Targets
Published: Mar 2022
5 citations
5 citations
164 days before retraction
The Effects of Increased Glucose Level and Glycolysis on SARS CoV-2 Infection
Mustafa Güzel, Fatma Özlem Zurnacı
Mini-Reviews in Medicinal Chemistry
Published: Mar 2022
4 citations
4 citations
165 days before retraction
Does Methylene Blue Satisfy an Option in COVID-19 ARDS
Sri Hari Tanguturi Yella, Sree Sudha Tanguturi Yella, K S B S Krishna Sasanka et al. (4 authors)
Infectious Disorders - Drug Targets
Published: Mar 2022
2 citations
2 citations
168 days before retraction
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3)
Amir Qaseem, Jennifer Yost, Itziar Etxeandia‐Ikobaltzeta et al. (8 authors)
Annals of Internal Medicine
Open Access
Published: Feb 2022
2 citations
2 citations
186 days before retraction
Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points
Anjum S. Kaka, Roderick MacDonald, Eric J. Linskens et al. (7 authors)
Annals of Internal Medicine
Open Access
Published: Feb 2022
48 citations
48 citations
186 days before retraction
A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
Hedyieh Karbasforooshan, Sofia Salari, Hesamoddin Hosseinjani
Infectious Disorders - Drug Targets
Published: Feb 2022
2 citations
2 citations
193 days before retraction
Quick Stats
Total Citations:
59
Years Since Retraction:
3.2 years
Open Access:
Yes
Last Checked:
Jul 24, 2025